

23 ~~31. (amended) A method of treating large cell anaplastic lymphoma (LCL), comprising administering an effective amount of a soluble CD30-L [according to claim 19] to a human afflicted with LCL.~~

Please add new claims 32 to 39, as follows:

32. A purified oligomer comprising CD30 ligand (CD30-L) polypeptides, wherein the CD30-L polypeptides are each selected from the group consisting of:

- Sub B1
- a) the murine CD30-L of SEQ ID NO:6;
 - b) the murine CD30-L of SEQ ID NO:19;
 - c) the human CD30-L of SEQ ID NO:8;
 - d) the human CD30-L of SEQ ID NO:23; and
 - e) a fragment of the CD30-L of (a), (b), (c), or (d);

wherein said oligomer binds CD30.

2 33. An oligomer according to claim 32, wherein said oligomer comprises three CD30-L polypeptides.

4 34. An oligomer according to claim 32, wherein each of the CD30-L polypeptides is a soluble fragment of the human CD30-L of SEQ ID NO:8 or SEQ ID NO:23.

6 35. An oligomer according to claim 34, wherein each of the CD30-L polypeptides is selected from the group consisting of a polypeptide comprising the extracellular domain of the human CD30-L of SEQ ID NO:23, and a fragment of said extracellular domain, wherein said fragment binds CD30.

5 36. An oligomer according to claim 34, wherein said oligomer comprises three CD30-L polypeptides.

7 37. An oligomer according to claim 36, wherein said oligomer comprises three CD30-L polypeptides.

3 38. An oligomer according to claim 37, wherein each of the CD30-L polypeptides is selected from the group consisting of:

a) a soluble CD30-L polypeptide comprising the extracellular domain of a CD30-L, encoded by a DNA sequence that will hybridize to the nucleotide sequence presented in SEQ ID NO:18 or SEQ ID NO:22 under moderately stringent conditions of 55°C in 5X SSC, and